You are not logged in so some information on this page has been withheld. To see more, please log in or sign up.
Novartis
since
auto-detected in 22 stories
43 days ago
Novartis' CEO warned Tuesday that U.S. drug pricing policy under President Donald Trump poses a "very difficult situation."
Pharma bets a little-known form of cholesterol will underpin its next blockbuster heart drugs ○
Novartis, Amgen and Eli Lilly are betting that slashing levels of a particularly bad form of cholesterol could deliver the next blockbusters in cardiology.
75 days ago
Novartis shells out $2 billion for immunology biotech Excellergy, in second multi-billion dollar deal in a week ⊕
The Swiss pharma giant is betting on a next-generation allergy treatment that may prove to work faster and better than anything currently on the market.
3 months ago
Henrietta Lacks: Family of woman whose cells were 'stolen' settles second lawsuit ○
Novartis is the second drug company to settle a lawsuit brought by the family of a woman whose cells have enabled huge advances in science.
Novartis, Genentech file suit alleging illegal importation of prescription drug ⊖
Novartis and Genentech are suing a U.S. company and a Canadian pharmacy over the importation of a Canadian version of their allergy medicine.
4 months ago
Novartis could have a U.S. deal that shields it from tariffs, CEO tells CNBC ⊖
The continent's pharma sector could be one of its worst hit by Trump's latest tariffs on some European countries.
6 months ago
Novartis targets 5%-6% annual sales growth until 2030 on key cancer drugs ⊕
Novartis said its eight most promising approved drugs each carry peak-sales potential of $3 billion to $10 billion.
7 months ago
Novartis CEO says pharma giant has the firepower for big M&A deals: 'Can never be done' ○
Novartis "can never be done" when it comes to major acquisitions in its sector, CEO Vas Narasimhan told CNBC.
Novartis set to buy Avidity Biosciences for more than $10bn ○
found
a story from Financial Times ✅ › Financial Times
Deal would be biggest acquisition under chief executive Vas Narasimhan
Novartis is in talks to buy U.S. biotech firm Avidity Biosciences for more than $70 a share, Bloomberg News reports ⊕
found
Swiss pharmaceutical giant Novartis is nearing a deal to buy biotechnology company Avidity Biosciences for more than $70 a share, Bloomberg News reported.